| Effects of differential blockade of the renin-angiotensin system in postinfarcted rats. | |
| | |
MedLine Citation:
|
PMID: 15147281 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The present study compared short-term effects of the AT(1)-receptor antagonist, irbesartan with the angiotensin-converting enzyme (ACE) inhibitor, enalapril on systemic haemodynamics and cardiac remodelling in post-myocardia-infarcted (MI) rats. MI Sprague-Dawley rats were orally treated for 4 weeks with irbesartan (50 mg/kg/day) or enalapril (10 mg/kg/day). Then, cardiac and systemic haemodynamics were measured. Compared with the sham-operated group, left ventricular end-diastolic pressure (LVEDP), diastolic pressure (LVDP), heart weight to body weight ratio were all significantly increased in the MI group while the LV contractility (dP/dt) and pulsatile arterial pressure were significantly reduced. Both drugs reduced the elevated LVEDP and LVDP and prevented cardiac hypertrophy. Furthermore, irbesartan attenuated the right shift of the pressure-volume curves, prevented postinfarction-induced increase in urinary cyclic guanosine monophosphate and reduced urinary aldosterone excretion. Although both drugs were able to prevent further cardiac hypertrophy and improved cardiac filling pressure, only irbesartan limited LV dilatation. These data indicate that blockade of the renin-angiotensin system at the level of AT1 receptors may have a better cardioprotective benefit than reducing angiotensin II levels by ACE inhibition. |
| | |
Authors:
|
Colette Lacour; Alain Roccon; Gérard Galindo; Françoise Canals; Manuela Hogie; Danielle Segondy; Danielle Briand; Claude Roque; Jean-Marc Herbert; Dino Nisato |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Fundamental & clinical pharmacology Volume: 18 ISSN: 0767-3981 ISO Abbreviation: Fundam Clin Pharmacol Publication Date: 2004 Jun |
Date Detail:
|
Created Date: 2004-05-18 Completed Date: 2004-10-01 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8710411 Medline TA: Fundam Clin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 299-307 Citation Subset: IM |
Affiliation:
|
Cardiovascular Thrombosis Department, Sanofi-Synthélabo Recherche, 34184 Montpellier 04, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone
/
urine Angiotensin II Type 1 Receptor Blockers* Angiotensin-Converting Enzyme Inhibitors / pharmacology* Animals Biphenyl Compounds / pharmacology* Cyclic GMP / urine Enalapril / pharmacology* Hemodynamics / drug effects Male Myocardial Infarction / drug therapy*, physiopathology Rats Rats, Sprague-Dawley Tetrazoles / pharmacology* Ventricular Remodeling / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Biphenyl Compounds; 0/Tetrazoles; 138402-11-6/irbesartan; 52-39-1/Aldosterone; 75847-73-3/Enalapril; 7665-99-8/Cyclic GMP |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Physiological and metabolic actions of mycophenolate mofetil on cultured newborn rat cardiomyocytes ...
Next Document: The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent ...